• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer

    9/14/21 8:27:00 AM ET
    $RFL
    Real Estate
    Finance
    Get the next $RFL alert in real time by email

    NEWARK, N.J., Sept. 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE:RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today the appointment of Patrick Fabbio as Chief Financial Officer.

    Rafael Holdings holds commercial real estate assets and interests in two clinical stage pharmaceutical companies. The pharmaceutical holdings consist of interests in Rafael Pharmaceuticals, Inc. and a majority stake in Lipomedix Pharmaceuticals Ltd., both of which are focused on development and commercialization of drugs in the oncology space. For more information, visit www.rafaelholdings.com

    "We are pleased to have attracted someone with Pat's extensive financial experience as we approach the completion and data readout of the Phase 3 registrational clinical trial for Rafael Pharmaceuticals' lead investigational agent, CPI-613®, for the treatment of metastatic pancreatic cancer expected in the fourth quarter of this year," said Ameet Mallik, Chief Executive Officer of Rafael Holdings, Inc.  "Pat joins our growing executive management team as we work to build a high growth, fully integrated cancer metabolism therapeutics company focused on improving and extending the lives of cancer patients."

    Pat Fabbio has more than 25 years of financial, operational and transactional leadership experience in both publicly-traded and privately-held life science and pharmaceutical companies. Prior to joining Rafael Holdings, Pat was Chief Financial Officer of WindMIL Therapeutics Inc. Previously he served as the Chief Financial Officer of Progenics Pharmaceuticals, Inc., electroCore Medical, LLC; Vice President of Finance at NPS Pharmaceuticals, Inc.; Vice President of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and Chief Financial Officer at Ikano Therapeutics. His other prior financial positions include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. Patrick is a board member of BeyondSpring Therapeutics, Inc. 

    "I am excited to work with Ameet and the Rafael Holdings team to build a commercial-ready leading cancer metabolism therapeutics company with the potential to address a large range of cancer indications and improve the lives of patients with unmet medical need," said Pat Fabbio, Chief Financial Officer.

    About Rafael Holdings, Inc.

    Rafael Holdings is focused on the development of novel cancer metabolism-based therapeutics.  The company owns the Barer Institute and is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.  Through its wholly owned Barer Institute subsidiary, the company is developing a pipeline of compounds focused on the regulation of cancer metabolism.  On June 21, 2021, Rafael Holdings, Inc., (NYSE:RFL) announced that it has entered into a merger agreement to acquire full ownership of Rafael Pharmaceuticals, Inc. For more information, visit www.rafaelholdings.com.

    About Rafael Pharmaceuticals, Inc.

    Rafael Pharmaceuticals is a clinical-stage oncology company focused on selectively targeting cancer metabolic pathways while simultaneously harnessing the immune system to attack hard-to-treat cancers. The Company's lead drug, CPI-613 (devimistat), is being evaluated in multiple clinical studies including two Phase 3 registrational clinical trials for metastatic pancreatic cancer and r/r acute myeloid leukemia. Multiple Phase 1/2 clinical trials are ongoing or planned in Biliary, r/r Burkitt, r/r Clear Cell Sarcoma, r/r T-cell lymphoma, r/r MDS, and Colorectal cancer. The Company's investors include Rafael Holdings, Inc. (NYSE:RFL). For more information, please visit www.rafaelpharma.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans and timing for the release of additional clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of public health threats, including COVID-19, on our business and operations; we depend heavily on the success of Rafael Pharmaceuticals and the future success of its lead product candidate devimistat (CPI-613® (devimistat)), and clinical trials of the product candidate may not be successful; our pharmaceutical companies may not be able to develop any medicines of commercial value; our pharmaceutical companies may not be successful in their efforts to identify or discover potential product candidates; the manufacturing and manufacturing development of our products and product candidates present technological, logistical and regulatory risks, each of which may adversely affect our potential revenue; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2020 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Cision View original content:https://www.prnewswire.com/news-releases/rafael-holdings-appoints-patrick-fabbio-as-chief-financial-officer-301376104.html

    SOURCE Rafael Holdings, Inc.

    Get the next $RFL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RFL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      9/30/24 5:40:03 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      6/18/24 6:12:11 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form SC 13D/A filed by Rafael Holdings Inc. (Amendment)

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Filed by)

      10/24/23 4:43:18 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    SEC Filings

    See more
    • Rafael Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      5/6/25 4:49:29 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form 424B3 filed by Rafael Holdings Inc.

      424B3 - Rafael Holdings, Inc. (0001713863) (Filer)

      5/6/25 4:40:50 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form 8-K/A filed by Rafael Holdings Inc.

      8-K/A - Rafael Holdings, Inc. (0001713863) (Filer)

      5/5/25 7:15:49 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Conkling William was granted 27,454 units of Class B Common Stock, increasing direct ownership by 5% to 564,455 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      4/24/25 3:18:53 PM ET
      $RFL
      Real Estate
      Finance
    • New insider Sieger Markus claimed ownership of 155,182 units of Class B Common Stock (SEC Form 3)

      3 - Rafael Holdings, Inc. (0001713863) (Issuer)

      4/2/25 10:56:32 AM ET
      $RFL
      Real Estate
      Finance
    • Chief Financial Officer Polinsky David covered exercise/tax liability with 2,378 units of Class B Common Stock, decreasing direct ownership by 1% to 193,540 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      3/25/25 4:40:08 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

      CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. ("Cornerstone" or the "Company"), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company's Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics. "Dr. Locasale is an internationally recognized leader in the use of metabolomics approaches to study cancer biology and metabolism," said Sanjeev Luther, President & CEO at Cornerstone Pharmaceutical

      7/6/22 8:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025. Former holders of Cyclo Therapeutics, Inc. who did not hold shares in street name and have not submitted their letter of transmittal to Equiniti Trust Company LLC (the Company's transfer agent), and wish to participate in the rights offering, should send their

      5/5/25 7:00:00 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants ("Holders") the opportunity to purchase additional shares of Rafael Holdings' Class B common stock, par value $0.01 per share ("Class B Common Stock"), subject to the terms outlined below for an aggregate offering of $25 million. The funds provide the Company additional capital for the potential launch of Trappsol® Cyclo™ in the event of a positive interim result from the 48-week interim analysis of the TransportNPC™ Phase 3 clinical t

      4/29/25 4:30:00 PM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced that, following the merger with Cyclo Therapeutics, Bill Conkling will be stepping down as CEO and assuming an advisory role with the Company. Rafael's Executive Chairman and Chairman of the Board, Howard Jonas will assume the role of CEO. During his tenure as CEO, Bill played a pivotal role in identifying investment opportu

      4/24/25 4:15:00 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Financials

    Live finance-specific insights

    See more
    • Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

      Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy Rafael Holdings to Host Conference Call Today at 8:00 a.m. ET NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals") as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phas

      10/28/21 7:00:00 AM ET
      $RFL
      Real Estate
      Finance